Abstract: The present invention relates to a method of obtaining peptides from procaryotic and/or eucaryotic cells.

Abstract: The present invention relates to a method of obtaining peptides from procaryotic and/or eucaryotic cells.

Abstract: The present invention relates to a method of obtaining peptides from procaryotic and/or eucaryotic cells.

Abstract: A device for preparing biological samples including a fixed support of which the base extends in a first plane, a filtration block that can be removable, the filtration block including a collecting tank that itself includes a filtering device extending in a second plane and dividing the collecting tank into a collection area and a suction area, the suction area being designed to be connected to a suction device, the second plane of the filtering device being inclined relative to the plane of the base of the fixed support.

Abstract: A device for preparing biological samples including a fixed support of which the base extends in a first plane, a filtration block that can be removable, the filtration block including a collecting tank that itself includes a filtering device extending in a second plane and dividing the collecting tank into a collection area and a suction area, the suction area being designed to be connected to a suction device, the second plane of the filtering device being inclined relative to the plane of the base of the fixed support.

Abstract: The present invention relates to a method of obtaining peptides from procaryotic and/or eucaryotic cells.

Abstract: The invention concerns a saturated or unsaturated abietane derivative of general formula (I) wherein: Z is selected among —COOR5, —CONR1R2, —COONR3R4, —COR6, —CON, —COOR5, —CHOHR7, —SR8, —OR8, —CN, —CNO, —CNS, —NCO, —NCS and —R1R2CR9; wherein R1, R2, R3 and R4 represent a hydrogen atom, a C1-C10 alkyl, a C6-C20 aryl optionally substituted, a C7-C10 alkene, a C1-C10 alkyne, or an aminoacyl or peptidyl optionally substituted; or R1 and R2 or R3 and R4 together form a cycle or a heterocycle; R5 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, a C1-C10 alkyne, or an aryl optionally substituted into C6-C20; R6 represents a hydrogen, a halogen, a C1-C10 alkyl, a C1-C10 alkene, a C1-C10 alkyne, or an aryl optionally substituted into C6-C20; R7 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, or a C1-C10 alkyne; R8 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, or a C1-C10 alkyne; and R9 is selected among

Abstract: The invention concerns novel cationic polymers of formula (I) in which n is a whole number between 0 and 5 and p is a whole number between 2 and 20,000, more particularly p ranges between 10 and 18,000, and advantageously between 200 and 1,000, characterized in that: at least 10%, advantageously 30 to 80%, preferably 70%, of the free NH2 functions are substituted by identical or different hydrophilic R groups; said cationic polymer can further comprise at least a targeting element associated covalently or not with the free NH2 functions and/or said hydrophilic R groups provided that said cationic: polymer contains at least 20%, preferably at least 30%, of free NH2 functions. The invention also concerns a complex comprising at least said cationic polymer associated with at least a therapeutically active substance, in particular a nucleic acid comprising at least a negative charge. The invention is useful for transferring a nucleic acid into target cells, in particular for gene therapy.

Abstract: The invention concerns novel cationic polymers of formula (I) in which n is a whole number between 0 and 5 and p is a whole number between 2 and 20000, more particularly p ranges between 10 and 18000, and advantageously between 200 and 1000, characterised in that: at least 10%, advantageously 30 to 80%, preferably 70%, of the free NH 2 functions are substituted by identical or different hydrophilic R groups; said cationic polymer can further comprise at least a targeting element associated covalently or not with the free NH 2 functions and/or said hydrophilic R groups provided that said cationic polymer contains at least 20%, preferably at least 30%, of free NH 2 functions. The invention also concerns a complex comprising at least said cationic polymer associated with at least a therapeutically active substance, in particular a nucleic acid comprising at least a negative charge. The invention is useful for transferring a nucleic acid into target cells, in particular for gene therapy.